Panobinostat for the Treatment of Multiple Myeloma

被引:229
作者
Laubach, Jacob P. [1 ]
Moreau, Philippe [2 ]
San-Miguel, Jesus F. [3 ]
Richardson, Paul G. [1 ]
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA
[2] Nantes Univ Hosp, Nantes, France
[3] Univ Navarra Clin, CIMA, IDISNA, Pamplona, Spain
关键词
PAN-DEACETYLASE INHIBITOR; LENALIDOMIDE PLUS DEXAMETHASONE; LOW-DOSE DEXAMETHASONE; SINGLE-AGENT; HISTONE DEACETYLASES; BORTEZOMIB; COMBINATION; CARFILZOMIB; LBH589; MULTICENTER;
D O I
10.1158/1078-0432.CCR-15-0530
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Panobinostat is a potent oral deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation. It was recently approved by the FDA and EMA for use in combination with bortezomib and dexamethasone in patients with multiple myeloma who have received >= 2 prior regimens, including bortezomib and an immunomodulatory drug. Panobinostat was approved based on results from the phase III PANORAMA 1 trial in patients with relapsed or relapsed and refractory multiple myeloma, which showed that panobinostat plus bortezomib and dexamethasone significantly extended progression- free survival (median, 12.0 months) compared with placebo plus bortezomib and dexamethasone (median, 8.1 months; P < 0.0001). Additional ongoing trials are evaluating panobinostat in combination with other partners in the relapsed/refractory and newly diagnosed treatment settings. This review focuses on panobinostat and its mechanism of action, pharmacokinetics, and clinical data in the treatment of relapsed or relapsed and refractory multiple myeloma. (C)2015 AACR.
引用
收藏
页码:4767 / 4773
页数:7
相关论文
共 40 条
[1]  
[Anonymous], J CLIN ONCOL S
[2]  
[Anonymous], P 56 ASH ANN M EXP 2
[3]  
[Anonymous], P 55 ASH ANN M EXP 2
[4]  
[Anonymous], P 56 ASH ANN M EXP 2
[5]  
[Anonymous], FARYDAK PAN CAPS OR
[6]  
[Anonymous], J CLIN ONCOL S
[7]  
[Anonymous], J CLIN ONCOL S
[8]   Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges [J].
Atadja, Peter .
CANCER LETTERS, 2009, 280 (02) :233-241
[9]   Efficacy and safety of once-weekly bortezomib in multiple myeloma patients [J].
Bringhen, Sara ;
Larocca, Alessandra ;
Rossi, Davide ;
Cavalli, Maide ;
Genuardi, Mariella ;
Ria, Roberto ;
Gentili, Silvia ;
Patriarca, Francesca ;
Nozzoli, Chiara ;
Levi, Anna ;
Guglielmelli, Tommasina ;
Benevolo, Giulia ;
Callea, Vincenzo ;
Rizzo, Vincenzo ;
Cangialosi, Clotilde ;
Musto, Pellegrino ;
De Rosa, Luca ;
Liberati, Anna Marina ;
Grasso, Mariella ;
Falcone, Antonietta P. ;
Evangelista, Andrea ;
Cavo, Michele ;
Gaidano, Gianluca ;
Boccadoro, Mario ;
Palumbo, Antonio .
BLOOD, 2010, 116 (23) :4745-4753
[10]   Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells [J].
Catley, Laurence ;
Weisberg, Ellen ;
Kiziltepe, Tanyel ;
Tai, Yu-Tzu ;
Hideshima, Teru ;
Neri, Paola ;
Tassone, Pierfrancesco ;
Atadja, Peter ;
Chauhan, Dharminder ;
Munshi, Nikhil C. ;
Anderson, Kenneth C. .
BLOOD, 2006, 108 (10) :3441-3449